Markel Group Inc. Raises Holdings in Novo Nordisk A/S $NVO

Markel Group Inc. boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 4.9% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,368,649 shares of the company’s stock after buying an additional 110,061 shares during the quarter. Markel Group Inc.’s holdings in Novo Nordisk A/S were worth $131,436,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. True Wealth Design LLC lifted its position in shares of Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after acquiring an additional 300 shares in the last quarter. NewSquare Capital LLC raised its stake in Novo Nordisk A/S by 174.1% in the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after purchasing an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. purchased a new position in Novo Nordisk A/S in the 2nd quarter valued at about $37,000. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth about $39,000. Finally, Copeland Capital Management LLC grew its holdings in shares of Novo Nordisk A/S by 47.3% during the second quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock worth $40,000 after buying an additional 186 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NVO stock opened at $63.96 on Tuesday. The company has a market cap of $285.58 billion, a PE ratio of 18.59 and a beta of 0.66. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. The stock has a 50-day moving average price of $52.44 and a two-hundred day moving average price of $54.54. Novo Nordisk A/S has a 12-month low of $43.08 and a 12-month high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The business had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. As a group, research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on NVO. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Hsbc Global Res lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. HSBC restated a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Morgan Stanley reiterated an “underweight” rating and set a $42.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. Finally, Jefferies Financial Group initiated coverage on Novo Nordisk A/S in a report on Monday, October 27th. They issued an “underperform” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus target price of $57.79.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.